Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553023 | 0.87 | TSHR (0.51) | ADORA2BTSHRRXFP1KMT2AMEN1 | |
| SCHEMBL515612 | 0.84 | RXFP1 (0.60) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| SCHEMBL5272641 | 0.81 | USP2 (0.51) | ADORA2BTSHRRXFP1KMT2ACYP2C19 | |
| SCHEMBL8664912 | 0.80 | TSHR (0.54) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| SCHEMBL1054300 | 0.80 | CYP2C19 (0.50) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| Niacin SCHEMBL7757829 | 0.80 | LMNA (0.51) | ADORA2BTSHRRXFP1KMT2AMAOA | |
| SCHEMBL8445876 | 0.78 | TSHR (0.48) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| Dimethylamine SCHEMBL11384972 | 0.76 | TSHR (0.61) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8421637 | 0.76 | TSHR (0.47) | TSHRRXFP1KMT2AMEN1CYP2C19 | |
| SCHEMBL28061963 | 0.76 | RXFP1 (0.59) | RXFP1KMT2AMEN1CYP2C19MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106692120-A | Medicine composition of lidocaine and application of medicine composition | 刘力 | 2017-05-24 | — | — | CN | claimed |
| CN-1957943-A | Injection of monoamine cysteine of glycyrrhizicacid and preparation | HE YAN (CN) | 2007-05-09 | — | — | CN | claimed |
| WO-2002022127-A1 | USE OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ANORECTAL DISORDERS | ISIS INNOVATION LIMITED (GB) | 2002-03-21 | — | — | WO | claimed |
| EP-0427247-B1 | Pharmaceutical composition with R-alpha-lipoic acid or S-alpha-lipoic acid as the active ingredient | ASTA MEDICA AG (DE) | 1998-03-11 | — | — | EP | claimed |
| EP-0812590-A2 | Use of R-alpha lipoic acid for cytoprotection | ASTA Medica Aktiengesellschaft (DE) | 1997-12-17 | — | — | EP | claimed |
| EP-0572922-A1 | Synergistic combinations comprising lipoic acid and vitamines in medicaments | ASTA Medica Aktiengesellschaft (DE) | 1993-12-08 | — | — | EP | claimed |
| EP-0427247-A2 | Pharmaceutical composition with R-alpha-lipoic acid or S-alpha-lipoic acid as the active ingredient | ASTA Medica Aktiengesellschaft (DE) | 1991-05-15 | — | — | EP | claimed |
| EP-0427246-A2 | Pharmaceutical compositions comprising sulfur containing carboxylic acids as the active agent as well as their use for combatting retroviruses | ASTA Medica Aktiengesellschaft (DE) | 1991-05-15 | — | — | EP | claimed |
| US-4423043-A | VETERINARY MEDICINE | CIBA-GEIGY CORPORATION (US) | 1983-12-27 | — | — | US | claimed |
| EP-0009559-B1 | STABLE, LIQUID PHARMACEUTICAL FORMULATION, ITS PREPARATION AND USE | CIBA-GEIGY AG (CH) | 1982-08-25 | — | — | EP | claimed |
| EP-0007591-B1 | STABLE MEDICINAL SOLUTION ON THE BASIS OF 2,6-DIAMINO-5-(3',4',5'-TRIMETHOXYBENZYL)-PYRIMIDINE(TRIMETHOPRIM) AND A SULPHONAMIDE, PROCESS FOR PREPARING AND USING IT | CIBA-GEIGY AG (CH) | 1982-07-28 | — | — | EP | claimed |
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115427050-A | Inhibition of beta-arrestin oligomerization in tauopathies | 南佛罗里达大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-115361948-A | Methods and compositions for inhibiting dihydroorotate dehydrogenase | 俄亥俄州国家创新基金会 | 2022-11-18 | — | — | CN | disclosed |
| CN-115335052-A | Methods and compositions for inhibiting dihydroorotate dehydrogenase in combination with anti-CD 38 therapeutics | 俄亥俄州国家创新基金会 | 2022-11-11 | — | — | CN | disclosed |
| US-4581359-A | FOR BRONCHOPULMONARY INSUFFUCIENCY | THE STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0059974-B1 | PROCESS FOR THE PREPARATION OF PHENOXYALCANECARBONIC-ACID ESTERS OF HYDROXYETHYL THEOPHYLINE | Ludwig Merckle GmbH & Co. chem.-pharm. Fabrik (DE) | 1985-07-31 | — | — | EP | disclosed |
| US-4423043-A | VETERINARY MEDICINE | CIBA-GEIGY CORPORATION (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0059974-A2 | Process for the preparation of phenoxyalcanecarbonic-acid esters of hydroxyethyl theophyline | Ludwig Merckle GmbH & Co. chem.-pharm. Fabrik (DE) | 1982-09-15 | — | — | EP | disclosed |
| EP-0009559-A1 | Stable, liquid pharmaceutical formulation, its preparation and use | CIBA-GEIGY AG (CH) | 1980-04-16 | — | — | EP | disclosed |